Advice
References
References
Ferreira J, Lees A, Rocha JF et al. (2016) Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. The Lancet Neurology 15(2), 154−65
Lees AJ, Ferreira J, Rascol O et al. (2016) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations. A randomized clinical trial. Journal of American Medical Association Neurology. Published online. doi:10.1001/jamaneurol.2016.4703
Peto V, Jenkinson C, Fitzpatrick R. (2001) Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age and Ageing 30(4), 299−302
Schrag A, Sampaio C, Counsell N et al. (2006) Minimal clinically important change on the unified Parkinson's disease rating scale. Movement disorders 21(8), 1200−07
Shulman L, Gruber‑Baldini A, Anderson K, et al. (2010) The clinically important difference on the unified Parkinson's disease rating scale. JAMA Neurology 67, 64−70